Navigation Links
DFB Sells Coria Labs to Valeant Pharmaceuticals
Date:9/17/2008

FORT WORTH, Texas, Sept. 17 /PRNewswire/ -- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., today announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to Valeant Pharmaceuticals International (NYSE: VRX).

Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from DFB Pharmaceuticals, Inc., and other shareholders for $95 million, subject to certain adjustments. The transaction is expected to close following the required approval under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended.

"This merger is an exciting milestone in the evolution of the Coria business," said Mr. Dorman. "Valeant has a commitment to the development and growth of its dermatology business, making it the ideal fit for Coria and its talented workforce here in Fort Worth as well as the field based sales representatives across the country. We see the combination of Coria with Valeant's financial strength as a way to maximize the past success of Coria and provide an outstanding platform to create a leading dermatology franchise."

The Coria transaction will add several marketed dermatology products to Valeant's portfolio, including the CeraVe(R) Skin Care Line, Cloderm(R) Cream for the treatment of dermatoses, Akne-Mycin(R) and Atralin(TM) for the treatment of acne, and Salex(R) for the treatment of hyperkeratotic skin disorders, as well as Tetrix(TM) Cream for the treatment of hand dermatitis which is expected to be launched later this year. In addition, Coria has several products under development, including line extensions for the CeraVe(R) brand product line.

Coria Laboratorie
'/>"/>

SOURCE DFB Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
4. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
5. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
6. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
9. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... BEIJING, May 1 Sinovac Biotech Ltd. (NYSE Amex: ... in China, today announced that it has filed its Annual ... Commission for the year ended December 31, 2008 on May ... now available on the Company,s website under the investor relations ...
... of $79.7 Million, Increase of 29% over First Quarter 2008- ... per Diluted Share, Increases of 14% and 20% over First ... Therapeutics Corporation (Nasdaq: UTHR ) today announced its ... Total revenues for the first quarter of 2009 were ...
... Earnings Conference Call to be Held on May 15, ... / 8:00 pm (Beijing/Shanghai/Hong Kong)SHANGHAI, May 1 /PRNewswire-Asia/ -- ... a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... today announced that it will release financial results for ...
Cached Biology Technology:Sinovac Biotech Ltd. Files Annual Report on Form 20-F 2United Therapeutics Reports First Quarter 2009 Financial Results 2United Therapeutics Reports First Quarter 2009 Financial Results 3United Therapeutics Reports First Quarter 2009 Financial Results 4United Therapeutics Reports First Quarter 2009 Financial Results 5United Therapeutics Reports First Quarter 2009 Financial Results 6United Therapeutics Reports First Quarter 2009 Financial Results 7WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... A - a potential agent of biological warfare and one ... able to sneak into cells. , The finding is ... paralytic illness caused by the toxin more commonly known as ... alleviate many medical problems, the recent work could help to ...
... found a common genetic variation in an immune system ... psoriasis ?a disfiguring inflammatory skin disease. , Named PSORS1 ... first genetic determinant of psoriasis to be definitively identified ... to new, more effective treatments for psoriasis without the ...
... that appear to play a significant role in the ... ability to form clots following an injury. They also ... may contribute to certain forms of leukemia. , "Basically, ... are turned off in normal platelet development, but turned ...
Cached Biology News:Scientists reveal how deadly toxin hijacks cells 2U-M scientists identify major psoriasis susceptibility gene 2U-M scientists identify major psoriasis susceptibility gene 3U-M scientists identify major psoriasis susceptibility gene 4MiRNA fingerprint identified in platelet formation 2
... Source: Streptomycin verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder ... pH (10 units/ml): 4.5 to 6.0 Loss On Drying: less ... equal to 0.1% Bleomycin Content: A 2 : 55 - ... B 2 : greater than or equal to 90% B ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of ... rabbits, monkeys and humans. 8-iso PGF2α ... lipid peroxidation. In both humans and ... primarily to metabolites having 2 or ...
Biology Products: